Is this mitochondria’s big moment?

Lausanne based Vandria is focused on rejuvenating cells in age-related and chronic disease by inducing the removal of damaged mitochondria

Are mitochondrial therapeutics about to go mainstream?

Distillery spotlight: new mitochondrial mechanisms from academia

Vandria begins clinical trials for Alzheimer’s drug VNA-318

Vandria begins clinical trials for promising mitophagy inducer

European Biotech Targeting Anti-ageing

Vandria Raises Second Series A; Round Totals $30.7M

Vandria closes Series A round at CHF28.3m